Non-survival group | Survival group | p-value | |
---|---|---|---|
(n = 52) | (n = 396) | ||
Sex (male) | 33 (63.5%) | 213 (53.8%) | 0.19 |
Age (years) | 82.5 ± 6.5 | 79.4 ± 5.7 | < 0.01 |
Follow-up period | 172.4 ± 109.7 | 1014.4 ± 605.5 | < 0.01 |
Operation type | 0.59 | ||
- arteriovenous fistula | 44 (84.6%) | 323 (81.6%) | |
- arteriovenous graft | 8 (15.4%) | 73 (18.4%) | |
Preoperative PLR | 158.2 ± 85.1 | 152.9 ± 76.0 | 0.67 |
Preoperative NLR | 5.6 ± 3.1 | 4.5 ± 2.6 | < 0.01 |
Preoperative MLR | 0.6 ± 0.3 | 0.5 ± 0.3 | 0.07 |
Diabetes mellitus | 37 (71.2%) | 336 (90.1%) | 0.01 |
COPD | 33 (63.5%) | 164 (41.4%) | < 0.01 |
Cancer | 11 (21.2%) | 41 (10.4%) | 0.02 |
Peripheral artery disease | 45 (86.5%) | 245 (61.9%) | < 0.01 |
Cerebrovascular disease | 24 (46.2%) | 173 (43.7%) | 0.74 |
Ischemic heart disease | 14 (26.9%) | 103 (26.0%) | 0.89 |
Liver disease | 14 (26.9%) | 83 (21.0%) | 0.33 |
Congestive heart failure | 9 (17.3%) | 46 (11.6%) | 0.24 |
Heart valve disease | 2 (3.8%) | 16 (4.0%) | 0.94 |